about
Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells.PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?O-linked glycosylation in the mammary gland: changes that occur during malignancy.Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.Characterizing the glycome of the mammalian immune system.Models of breast morphogenesis based on localization of stem cells in the developing mammary lobuleAutoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.Selection of a Relevant In Vitro Blood-Brain Barrier Model to Investigate Pro-Metastatic Features of Human Breast Cancer Cell LinesElevated IgG4 in patient circulation is associated with the risk of disease progression in melanomaFunctional analysis of the transcription repressor PLU-1/JARID1B.Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers.Immunisation with 'naïve' syngeneic dendritic cells protects mice from tumour challenge.Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cellsAutoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancerIdentification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.MUC1 immunotherapy.Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers.Interactions of mucins with the Tn or Sialyl Tn cancer antigens including MUC1 are due to GalNAc-GalNAc interactions.Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.The role of tumor-associated antigens in the biology and immunotherapy of breast cancer.Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.Differential effect of interferon on DNA synthesis, 2-deoxyglucose uptake and ornithine decarboxylase activity in 3T3 cells stimulated by polypeptide growth factors and tumor promotors.NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3.Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase.Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis.Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma.Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer.Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer.
P50
Q24311744-47E6D0C2-8D4E-417A-A9F1-886A98A9811BQ33729654-446A031A-173E-4F5A-95CD-F074BB0EADD2Q34149986-D07C1491-80A2-4F9B-8353-5D6BC93497B6Q34362815-D4D9893A-09F1-44E1-94F7-DC140D278202Q34406488-011B21AB-26ED-4147-BAAB-DCA0CA9D9C99Q34411297-D27353AF-1FB4-4B42-9E8E-E4568FEACACFQ34471553-4EF67DC5-499D-4041-B96A-584AB955011CQ34522222-A21C7DF4-86C9-48ED-A8B4-CD3FC12FC34FQ34610411-24A7BAA6-2FFE-403F-AF6F-E75071D642CDQ34813256-6C8EB27A-B3D6-4E62-A4DF-F4D5344D0D74Q35453612-85A27ABA-4F2A-4726-B26D-9C8ECB3C1677Q35558939-5E51B635-D897-4AF5-965C-DF501E322B6EQ35581939-84DA05CF-C3EC-4641-8CBD-E6E97D63670CQ35950790-B0FD524A-ED58-4956-B5BA-FD363255DD2EQ36110293-5B695C79-7375-46CE-B258-1D61EED86C4CQ36315263-2A222619-2D15-4A0B-B6D0-1E8AE63F24E7Q36348610-F8342AF5-C850-4464-9E2C-1E9D7341E032Q36484597-8971BDDA-61B7-408D-9F57-AAEF68CA66F5Q36787387-9322360D-D3BF-403C-A88A-42F12E73E9D5Q36896106-D408A371-F25C-429D-A750-BFF318952AF0Q37295526-AABA610C-77E7-43AF-A9C2-C2AAA63696C9Q37533025-AF6DA7D0-437F-46AE-8552-963D658FB70AQ37600827-2194BD0C-20FB-4608-90C7-04F6C1B14DE3Q37773241-0945D1F9-8388-44FA-A984-F9AC3AEF664CQ39453175-6933B2F8-6F66-48A4-B04C-3A7A5A878569Q39696121-A13D219E-9379-4105-84F3-180BCA422400Q40365052-2A1225EC-B992-490E-9C8E-089441503E8CQ40416661-967FC6C8-1ED7-4E18-93EC-9D26F11BD1C5Q40800301-DC57D057-961F-4F92-9325-4E5AC9C09E24Q41282220-0222D349-067A-40E9-B000-8B6750F589E1Q42828436-C41C5616-9433-40BB-95F9-069FCD0D4F27Q43902828-A766BE7D-302D-4420-84FB-8FBCAC7EFB98Q43942079-16EB595B-6EA7-409B-BBE0-7C7ABA90CAB2Q44839641-F58E142E-D495-4E15-B843-EEEDAB836759Q45084810-71366E45-9354-444F-B7B2-45E16B37A1E3Q45190065-BDDB3E94-5477-4BD7-A3D7-C100BD0CDF5FQ47423101-A8F9D6DB-9170-4F53-9BEC-C40335823D3AQ47705298-F8A931DA-9FDF-4568-BC1E-177CE0A03E38Q48185324-E52FD904-7C5F-46FB-A05A-133B210A5E6BQ48257208-0E04A6D5-6FC7-445B-846C-C45385DDA77C
P50
description
researcher ORCID ID = 0000-0003-0413-3823
@en
name
Joy M Burchell
@ast
Joy M Burchell
@en
Joy M Burchell
@es
Joy M Burchell
@nl
type
label
Joy M Burchell
@ast
Joy M Burchell
@en
Joy M Burchell
@es
Joy M Burchell
@nl
prefLabel
Joy M Burchell
@ast
Joy M Burchell
@en
Joy M Burchell
@es
Joy M Burchell
@nl
P1153
7003872134
P31
P496
0000-0003-0413-3823